AU-15330 Biochemical

AU-15330

Cat. Num. AAA228381

• Purity: 98%
• Synonyms: AU-15330; N/A; AU-15330 biochemical

• Purity/Purification: 98%

• CAS: 2380274-50-8
• Solubility: <1mg/ml refers to the product slightly soluble or insoluble
• In vitro: AU-15330 (10 and 30 mg/kg; i.v.; 5 days per week for 3 weeks) shows no evident toxicity in immuno-competent mice[1]. AU-15330 (60 mg/kg with or without 10mg/kg enzalutamide; i.v.; 3 days per week; p.o.; 5 days per week for 5 weeks) leads to potent inhibition of tumour growth, triggering disease regression in more than 20% of animals. Combinatorial regimen induced the most potent anti-tumour effect, with regression in all animals[1]. AU-15330 (60 mg/kg with or without 10mg/kg enzalutamide; i.v.; 3 days per week; p.o.; 5 days per week for 5 weeks) strongly inhibits the growth of C4-2B cell line-derived CRPC xenografts in intact mice as a single agent and synergized with enzalutamide[1]. AU-15330 (60 mg/kg with or without 10mg/kg enzalutamide; i.v.; 3 days per week; p.o.; 5 days per week for 5 weeks) combines with enzalutamide induces significant tumour growth inhibition, causing regression in more than 30% of animals in the modle of CRPC variant of the MDA-PCa-146-12 PDX by tumour implantation into castrated mice[1]. Animal Model: Six-week-old male CB17 severe combined immunodeficiency (SCID) mice[1]. Dosage: 10 and 30 mg/kg. Administration: i.v. (5 days per week for 3 weeks). Result: Showed no evident toxicity in immuno-competent mice. Animal Model: VCaP castration-resistant tumour model (six-week-old male CB17 severe combined immunodeficiency (SCID) mice)[1]. Dosage: 60 mg/kg with or without 10mg/kg enzalutamide. Administration: i.v. (3 days per week); p.o. (5 days per week for 5 weeks). Result: Resulted inhibition of tumor growth and triggered disease regression in more than 20% of animals. Combinatorial regimen induced the most potent anti-tumour effect, with regression in all animals. Animal Model: C4-2B non-castrated tumour model (six-week-old male CB17 severe combined immunodeficiency (SCID) mice)[1]. Dosage: 60 mg/kg with or without 3mg/kg enzalutamide. Administration: i.v. (3 days per week); p.o. (5 days per week for 4 weeks). Result: Strongly inhibited the growth of C4-2B cell line-derived CRPC xenografts in intact mice as a single agent and synergized with enzalutamide.
• Preparation and Storage: Powder: -20 degree C for 3 years; In solvent: -80 degree C for 2 years

Structure

(Fmoc-Leu-Ser(psi(Me,Me)pro)-OH, CAS 339531-50-9)

Structure

(Fmoc-Leu-Ser(psi(Me,Me)pro)-OH, CAS 339531-50-9)

Related Product Information for AU-15330 biochemical

AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide. AU-15330 induces disease remission in castration-resistant prostate cancer (CRPC) models without toxicity.